Ardelyx Inc FDA Update On Tenapanor For Hyperphosphatemia NDA Corporate Call Transcript
Good afternoon, and welcome to Ardelyx's conference call. (Operator Instructions)
As a reminder, today's call is being recorded. I would now like to turn the call over to Kimia Keshtbod, Manager of Corporate Communications. You may begin.
Thank you, and good afternoon, everyone. During this call, we will refer to the press release issued today, which is available in the Investors section of the company's website at ardelyx.com. On the call with me today are Mike Raab, President and CEO, with prepared remarks. Dr. David Rosenbaum, Chief Development Officer; Susan Rodriguez, Chief Commercial Officer; Justin Renz, Chief Financial Officer; and Rob Blanks, Chief Regulatory Affairs and Quality Assurance Officer, will join us for the question-and-answer period.
During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ materially from those described. We encourage you to review our risk factors
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
